Montpellier, France — January 14th, 2021 — CILcare, the world-leading CRO specialized in the field of hearing, recently had the immense pleasure of welcoming Dr. Mathieu Schué to the team as Project Director of Drug Development & Translational Research. In this role, Mathieu Schué will dive into CILcare’s preclinical models and read-outs, validate reference compounds for various hearing indications, and identify innovative development strategies to support preclinical to clinical drug translation and continuously improve CILcare’s support to its clients and partners.
With over 15 years of experience in the management of drug development projects, Mathieu Schué has successfully brought drug candidates from preclinical to clinical phases, especially in areas of unmet medical needs where a path to success has yet to be paved. Prior to joining CILcare, Mathieu managed R&D operations including compound selection, targeting profile definitions, and market positioning, in a biotech company specialized in the development of therapeutic proteins for the treatment of patients with cystic fibrosis and chronic pancreatitis. Within a multidisciplinary team, he guided service providers and handled the preparation of regulatory documents, including Pre-IND, typeC meeting, and IND/IMPD packages to support Phase 2 CTA, directly interacting with Health Authorities.
“I am delighted and excited to be joining CILcare’s great team” underlines Mathieu. “I believe CILcare has unmatched expertise in the field of hearing with strong business values that uniquely position us as a catalyst of novel therapies to prevent and treat hearing loss, tinnitus, and otitis. I look forward to contributing to CILcare’s future success as the company progresses towards the next phase of its strategy.”
At CILcare, Mathieu will lead projects to define development plan strategies of drug candidates specifically designed for hearing disorders, based on an extensive review of regulation, competitive intelligence, predictability of preclinical models, and clinical assays. In collaboration with CILcare’s COO and CSO, he will be accountable for identifying reference compounds for different hearing indications, as well as developing scientifically rigorous translational and exploratory biomarker strategies that assess proof of mechanism, establish early signs of efficacy, enable proof of concept studies, and patient selection.
The goal is to provide CILcare’s Sponsors with innovative translational strategies to rapidly advance promising drug candidates to clinical phases and ultimately, to the market.
“One of our top priorities is the total satisfaction of our clients, and Mathieu’s level of experience and vast knowledge of drug development & regulatory processes will ensure that we continue to exceed our customers’ expectations. We are excited to have him onboard with his great potential which strengthens our expertise in translational science, a key area in the hearing field. We are very pleased to welcome him to the team” comments Marie-Pierre Pasdelou, Chief Regulatory Officer and co-founder.
Mathieu Schué graduated from Birmingham University (UK) with a PhD in molecular microbiology.
CBSET is a state-of-the-art biomedical research institute located in Lexington, Mass. As a not-for-profit entity, our mission is to advance biomedical research through innovative, high-quality preclinical services to achieve the scientific, regulatory and commercial goals of our sponsors. Our 40,000-foot, GLP-compliant, OLAW-assured, AAALAC-accredited facility includes vivaria, procedure rooms, catheterization / imaging labs, surgical and necropsy suites, histopathology, SEM, and a range of other technologies. We provide top-tier research with operational expertise by combining in vivo studies, in vitro studies, computational and 3D modeling, and complex histopathology into one integrated paradigm. Since inception, CBSET continues to develop technical and scientific acumen through collaborative projects in the medical device, pharmaceutical and academic communities. Learn more about CBSET’s expert biomedical research services.
CILcare, with headquarters in Montpellier, France, and offices in Paris and Boston, is a CRO specializing in otology. CILcare has state-of-the-art laboratories, research experts in otology and neuroscience, as well as a global network of partners, enabling CILcare to offer fully customizable and comprehensive R&D programs including pharmacokinetics, preclinical efficacy, and GLP ototoxicology studies. Learn more about CILcare’s expert R&D services dedicated to ear disorders.